A detailed history of Cibc Asset Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cibc Asset Management Inc holds 368,946 shares of BMY stock, worth $21.5 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
368,946
Previous 337,962 9.17%
Holding current value
$21.5 Million
Previous $14 Million 36.03%
% of portfolio
0.07%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$39.66 - $51.75 $1.23 Million - $1.6 Million
30,984 Added 9.17%
368,946 $19.1 Million
Q2 2024

Aug 01, 2024

SELL
$40.25 - $52.99 $2.66 Million - $3.5 Million
-66,073 Reduced 16.35%
337,962 $14 Million
Q1 2024

May 09, 2024

BUY
$47.98 - $54.4 $2.58 Million - $2.93 Million
53,773 Added 15.35%
404,035 $21.9 Million
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $1.01 Million - $1.2 Million
-20,737 Reduced 5.59%
350,262 $18 Million
Q3 2023

Oct 30, 2023

SELL
$57.89 - $64.73 $602,113 - $673,256
-10,401 Reduced 2.73%
370,999 $21.5 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $359,196 - $398,832
-5,638 Reduced 1.46%
381,400 $24.4 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $190,624 - $216,211
2,901 Added 0.76%
387,038 $26.8 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $7.16 Million - $8.48 Million
-104,542 Reduced 21.39%
384,137 $27.6 Million
Q3 2022

Nov 03, 2022

BUY
$0.13 - $76.84 $7,524 - $4.45 Million
57,883 Added 13.44%
488,679 $34.7 Million
Q2 2022

Aug 09, 2022

BUY
$72.62 - $79.98 $1.16 Million - $1.28 Million
15,959 Added 3.85%
430,796 $33.2 Million
Q1 2022

May 06, 2022

BUY
$61.48 - $73.72 $2.35 Million - $2.81 Million
38,156 Added 10.13%
414,837 $30.3 Million
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $1.78 Million - $2.07 Million
33,186 Added 9.66%
376,681 $23.5 Million
Q3 2021

Nov 09, 2021

BUY
$59.17 - $69.31 $304,311 - $356,461
5,143 Added 1.52%
343,495 $20.3 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $15,663 - $17,057
253 Added 0.07%
338,352 $22.6 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $3.6 Million - $4.05 Million
-60,743 Reduced 15.23%
338,099 $21.3 Million
Q4 2020

Feb 03, 2021

BUY
$57.74 - $65.43 $1.26 Million - $1.42 Million
21,772 Added 5.77%
398,842 $24.7 Million
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $1.03 Million - $1.14 Million
17,883 Added 4.98%
377,070 $22.7 Million
Q2 2020

Jul 28, 2020

BUY
$54.82 - $64.09 $7.75 Million - $9.05 Million
141,281 Added 64.84%
359,187 $21.1 Million
Q1 2020

Apr 30, 2020

SELL
$46.4 - $67.43 $127,182 - $184,825
-2,741 Reduced 1.24%
217,906 $12.1 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $3.27 Million - $4.27 Million
66,526 Added 43.16%
220,647 $14.2 Million
Q3 2019

Oct 30, 2019

BUY
$42.77 - $50.71 $304,180 - $360,649
7,112 Added 4.84%
154,121 $7.82 Million
Q2 2019

Aug 05, 2019

BUY
$44.62 - $49.34 $6,202 - $6,858
139 Added 0.09%
147,009 $6.67 Million
Q1 2019

May 06, 2019

SELL
$45.12 - $53.8 $71,334 - $85,057
-1,581 Reduced 1.06%
146,870 $7.01 Million
Q4 2018

Feb 12, 2019

SELL
$48.76 - $63.23 $105,857 - $137,272
-2,171 Reduced 1.44%
148,451 $7.72 Million
Q3 2018

Nov 02, 2018

SELL
$55.19 - $62.25 $68,270 - $77,003
-1,237 Reduced 0.81%
150,622 $9.35 Million
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $278,218 - $346,767
5,506 Added 3.76%
151,859 $8.4 Million
Q1 2018

Apr 30, 2018

SELL
$59.92 - $68.98 $469,832 - $540,872
-7,841 Reduced 5.09%
146,353 $9.26 Million
Q4 2017

Feb 02, 2018

BUY
$59.94 - $65.35 $140,379 - $153,049
2,342 Added 1.54%
154,194 $9.45 Million
Q3 2017

Nov 06, 2017

BUY
$55.23 - $63.74 $8.39 Million - $9.68 Million
151,852
151,852 $9.68 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.